Read by QxMD icon Read


Eric H Kim, John K Weaver, Anup S Shetty, Joel M Vetter, Gerald L Andriole, Seth A Strope
OBJECTIVES: To determine the added value of prostate MRI to the Prostate Cancer Prevention Trial risk calculator. METHODS: Between January 2012 and December 2015, 339 patients underwent prostate MRI prior to biopsy at our institution. MRI was considered positive if there was at least one Prostate Imaging Reporting and Data System 4 or 5 MRI suspicious region. Logistic regression was used to develop two models: biopsy outcome as a function of the 1) Prostate Cancer Prevention Trial risk calculator alone, and 2) combined with MRI findings...
December 2, 2016: Urology
Paul F Pinsky, Philip C Prorok, Kelly Yu, Barnett S Kramer, Amanda Black, John K Gohagan, E David Crawford, Robert L Grubb, Gerald L Andriole
BACKGROUND: Two large-scale prostate cancer screening trials using prostate-specific antigen (PSA) have given conflicting results in terms of the efficacy of such screening. One of those trials, the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, previously reported outcomes with 13 years of follow-up. This study presents updated findings from the PLCO trial. METHODS: The PLCO trial randomized subjects from 1993 to 2001 to an intervention or control arm...
December 1, 2016: Cancer
Robert S Wang, Eric H Kim, Joel M Vetter, Kathryn J Fowler, Anup S Shetty, Aaron J Mintz, Niraj G Badhiwala, Robert L Grubb, Gerald L Andriole
OBJECTIVES: To assess the negative predictive value (NPV) of multi-parametric MRI (mpMRI) for detection of prostate cancer (PCa) in routine clinical practice, and to identify characteristics of patients for whom mpMRI fails to detect high-grade (Gleason ≥7) disease. METHODS: We reviewed our prospectively maintained database of consecutive men who received prostate mpMRI at our institution, interpreted by a clinical practice of academic radiologists. Between January 2012 and December 2015, 84 men without any MR suspicious regions (MSRs) according to prior institutional classification, or with PI-RADS 1-2 lesions according to the PI-RADS system, underwent standard template transrectal ultrasound-guided (TRUS) prostate biopsy...
November 11, 2016: Urology
Eric H Kim, Gerald L Andriole, E David Crawford, Daniel D Sjoberg, Melissa Assel, Andrew J Vickers, Hans Lilja
PURPOSE: To assess the performance of a four-kallikrein panel, with and without microseminoprotein-beta (MSP), to predict high-grade (Gleason 7+, Gleason Grade Group 2+) prostate cancer (PCa) on biopsy in a multiethnic cohort from the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial. MATERIALS AND METHODS: Levels of free, intact, total prostate-specific antigen (PSA), human kallikrein-2, and MSP were measured blinded to outcome in cryo-preserved serum from men in the intervention arm of PLCO...
October 31, 2016: Journal of Urology
Dorothy A Sippo, Robyn L Birdwell, Katherine P Andriole, Sughra Raza
No abstract text is available yet for this article.
September 24, 2016: Journal of the American College of Radiology: JACR
Adriana C Vidal, Zinan Chen, Lauren E Howard, Daniel M Moreira, Ramiro Castro-Santamaria, Gerald L Andriole, Emanuela Taioli, Jay H Fowke, Beatrice Knudsen, Charles G Drake, J Curtis Nickel, Stephen J Freedland
Prostate cancer (PC) risk differs between races, and we previously showed prostate inflammation in benign prostate tissue was linked with a lower future PC risk. However, whether prostate tissue inflammation varies by race is unknown. We analyzed baseline acute and chronic prostate inflammation by race in REDUCE, a 4-year, multicenter, placebo-controlled study where all men had a negative prostate biopsy prior to enrollment. We included 7,982 men with standardized central pathology review to determine the presence or absence of chronic or acute inflammation in baseline prostate biopsy tissue...
July 18, 2016: Oncotarget
Dorothy A Andriole, Donna B Jeffe, Robert H Tai
No abstract text is available yet for this article.
July 2016: Public Health Reports
Katherine P Andriole
No abstract text is available yet for this article.
October 2016: Journal of the American College of Radiology: JACR
Cynthia S Gadd, Jeffrey J Williamson, Elaine B Steen, Katherine P Andriole, Connie Delaney, Karl Gumpper, Martin LaVenture, Doug Rosendale, Dean F Sittig, Thankam Thyvalikakath, Peggy Turner, Douglas B Fridsma
AMIA is leading the effort to strengthen the health informatics profession by creating an advanced health informatics certification (AHIC) for individuals whose informatics work directly impacts the practice of health care, public health, or personal health. The AMIA Board of Directors has endorsed a set of proposed AHIC eligibility requirements that will be presented to the future AHIC certifying entity for adoption. These requirements specifically establish who will be eligible to sit for the AHIC examination and more generally signal the depth and breadth of knowledge and experience expected from certified individuals...
July 2016: Journal of the American Medical Informatics Association: JAMIA
Luigi Fontana, Nicole E Cummings, Sebastian I Arriola Apelo, Joshua C Neuman, Ildiko Kasza, Brian A Schmidt, Edda Cava, Francesco Spelta, Valeria Tosti, Faizan A Syed, Emma L Baar, Nicola Veronese, Sara E Cottrell, Rachel J Fenske, Beatrice Bertozzi, Harpreet K Brar, Terri Pietka, Arnold D Bullock, Robert S Figenshau, Gerald L Andriole, Matthew J Merrins, Caroline M Alexander, Michelle E Kimple, Dudley W Lamming
Protein-restricted (PR), high-carbohydrate diets improve metabolic health in rodents, yet the precise dietary components that are responsible for these effects have not been identified. Furthermore, the applicability of these studies to humans is unclear. Here, we demonstrate in a randomized controlled trial that a moderate PR diet also improves markers of metabolic health in humans. Intriguingly, we find that feeding mice a diet specifically reduced in branched-chain amino acids (BCAAs) is sufficient to improve glucose tolerance and body composition equivalently to a PR diet via metabolically distinct pathways...
July 12, 2016: Cell Reports
Kaveri S Parker, Jan R Crowley, Alisa J Stephens-Shields, Adrie van Bokhoven, M Scott Lucia, H Henry Lai, Gerald L Andriole, Thomas M Hooton, Chris Mullins, Jeffrey P Henderson
Interstitial cystitis/bladder pain syndrome (IC/BPS) is a poorly understood syndrome affecting up to 6.5% of adult women in the U.S. The lack of broadly accepted objective laboratory markers for this condition hampers efforts to diagnose and treat this condition. To identify biochemical markers for IC/BPS, we applied mass spectrometry-based global metabolite profiling to urine specimens from a cohort of female IC/BPS subjects from the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network...
May 2016: EBioMedicine
Samir S Taneja, James Bennett, Jonathan Coleman, Robert Grubb, Gerald Andriole, Robert E Reiter, Leonard Marks, Abdel-Rahmene Azzouzi, Mark Emberton
PURPOSE: Vascular targeted photodynamic therapy with WST11 (TOOKAD® Soluble) is a form of tissue ablation that may be used therapeutically for localized prostate cancer. To study dosing parameters and associated treatment effects we performed a prospective, multicenter, phase I/II trial of WST11 vascular targeted photodynamic therapy of prostate cancer. MATERIALS AND METHODS: A total of 30 men with unilateral, low volume, Gleason 3 + 3 prostate cancer were enrolled at 5 centers after local institutional review board approval...
October 2016: Journal of Urology
Brandon J Manley, John A Brockman, Valary T Raup, Kathryn J Fowler, Gerald L Andriole
INTRODUCTION: The use of multi-parametric (MP) MRI to diagnose prostate cancer has been the subject of intense research, with many studies showing positive results. The purpose of our study is to better understand the accessibility, role, and perceived accuracy of MP-MRI in practice by surveying practicing urologists. MATERIALS AND METHODS: Surveys were sent to 7,400 practicing American Urological Association member physicians with a current email address. The survey asked demographic information and addressed access, accuracy, cost, and role of prostate MRI in clinical practice...
May 2016: International Braz J Urol: Official Journal of the Brazilian Society of Urology
Mark I Evans, Stephanie Andriole, Shara M Evans
The choice of screening or invasive procedure in twin pregnancies is a personal choice of whether the patient wishes to take a small risk of having a baby with a serious disorder versus a small risk of having a complication because she wishes to avoid that. How to interpret such risks has profound effects on the perceived value of techniques, either leading to a decision to screening or going directly to chorionic villus sampling. There are profound issues surrounding the data and the interpretation of the data...
June 2016: Clinics in Laboratory Medicine
Avory M Heningburg, Anand Mohapatra, Aaron M Potretzke, Alyssa Park, Alethea G Paradis, Joel Vetter, Adrienne N Kuxhausen, Leslie D McIntosh, Anthony Juehne, Alana C Desai, Gerald L Andriole, Brian M Benway
PURPOSE: To evaluate a physician's impression of a urinary stone patient's dietary intake and whether it was dependent on the medium through which the nutritional data were obtained. Furthermore, we sought to determine if using an electronic food frequency questionnaire (FFQ) impacted dietary recommendations for these patients. MATERIALS AND METHODS: Seventy-six patients attended the Stone Clinic over a period of 6 weeks. Seventy-five gave consent for enrollment in our study...
May 2016: Investigative and Clinical Urology
Dorothy A Andriole, Donna B Jeffe
PURPOSE: The authors sought to identify variables associated with MD-PhD program graduates' academic medicine careers. METHODS: We analyzed data for a national cohort of MD-PhD program graduates from 2000 to 2005, using multivariable logistic regression to identify independent predictors of full-time academic medicine faculty appointment through 2013. RESULTS: Of 1,860 MD-PhD program graduates in 2000-2005, we included 1,846 (99.2%) who had completed residency training before 2014...
2016: Medical Education Online
Peter R Carroll, J Kellogg Parsons, Gerald Andriole, Robert R Bahnson, Erik P Castle, William J Catalona, Douglas M Dahl, John W Davis, Jonathan I Epstein, Ruth B Etzioni, Thomas Farrington, George P Hemstreet, Mark H Kawachi, Simon Kim, Paul H Lange, Kevin R Loughlin, William Lowrance, Paul Maroni, James Mohler, Todd M Morgan, Kelvin A Moses, Robert B Nadler, Michael Poch, Chuck Scales, Terrence M Shaneyfelt, Marc C Smaldone, Geoffrey Sonn, Preston Sprenkle, Andrew J Vickers, Robert Wake, Dorothy A Shead, Deborah A Freedman-Cass
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer Early Detection provide recommendations for prostate cancer screening in healthy men who have elected to participate in an early detection program. The NCCN Guidelines focus on minimizing unnecessary procedures and limiting the detection of indolent disease. These NCCN Guidelines Insights summarize the NCCN Prostate Cancer Early Detection Panel's most significant discussions for the 2016 guideline update, which included issues surrounding screening in high-risk populations (ie, African Americans, BRCA1/2 mutation carriers), approaches to refine patient selection for initial and repeat biopsies, and approaches to improve biopsy specificity...
May 2016: Journal of the National Comprehensive Cancer Network: JNCCN
Eric H Kim, Gerald L Andriole
No abstract text is available yet for this article.
September 2016: Journal of the National Cancer Institute
Juzar Jamnagerwalla, Lauren E Howard, Adriana C Vidal, Daniel M Moreira, Ramiro Castro-Santamaria, Gerald L Andriole, Stephen J Freedland
PURPOSE: Despite routine use of phosphodiesterase type 5 inhibitor to treat erectile dysfunction the role in prostate cancer chemoprevention remains unclear. Only a few studies have explored the link between phosphodiesterase type 5 inhibitor use and prostate cancer. We tested the association between phosphodiesterase type 5 inhibitor and prostate cancer risk in the REDUCE (Reduction by Dutasteride of Prostate Cancer Events) trial. MATERIALS AND METHODS: REDUCE was a 4-year multicenter study testing the effect of daily dutasteride on prostate cancer risk in men with prostate specific antigen 2...
September 2016: Journal of Urology
James McKiernan, Michael J Donovan, Vince O'Neill, Stefan Bentink, Mikkel Noerholm, Susan Belzer, Johan Skog, Michael W Kattan, Alan Partin, Gerald Andriole, Gordon Brown, John T Wei, Ian M Thompson, Peter Carroll
IMPORTANCE: Overdiagnosis and overtreatment of indolent prostate cancer (PCA) is a serious health issue in most developed countries. There is an unmet clinical need for noninvasive, easy to administer, diagnostic assays to help assess whether a prostate biopsy is warranted. OBJECTIVE: To determine the performance of a novel urine exosome gene expression assay (the ExoDx Prostate IntelliScore urine exosome assay) plus standard of care (SOC) (ie, prostate-specific antigen [PSA] level, age, race, and family history) vs SOC alone for discriminating between Gleason score (GS)7 and GS6 and benign disease on initial biopsy...
July 1, 2016: JAMA Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"